# TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer

> **NCT05993702** · — · UNKNOWN · sponsor: **China Medical University, China** · enrollment: 45 (estimated)

## Conditions studied

- TAS 102
- Regorafenib
- Fruquintinib
- Gastrointestinal Tumours

## Interventions

- **DRUG:** regorafenib
- **DRUG:** fruquintinib

## Key facts

- **NCT ID:** NCT05993702
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05993702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05993702, "TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05993702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*